Botanix Pharmaceuticals Limited
BXPHF
$0.25
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 374.95% | -1.55% | -46.24% | -76.46% | -93.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 374.95% | -1.55% | -46.24% | -76.46% | -93.58% |
| Cost of Revenue | 139.32% | 2.45% | -37.60% | -70.24% | -86.31% |
| Gross Profit | -52.89% | -7.79% | 20.96% | 60.89% | 76.58% |
| SG&A Expenses | 363.22% | 252.23% | 96.10% | 66.68% | 37.33% |
| Depreciation & Amortization | 1,035.32% | 485.89% | -36.06% | -16.33% | 8.52% |
| Other Operating Expenses | -49.66% | -58.58% | -65.02% | -43.67% | -16.83% |
| Total Operating Expenses | 303.94% | 150.58% | 21.54% | -17.00% | -43.78% |
| Operating Income | -300.87% | -183.61% | -49.46% | -12.62% | 15.53% |
| Income Before Tax | -290.08% | -176.78% | -47.71% | -11.89% | 15.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -290.08% | -176.78% | -47.71% | -11.89% | 15.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -290.08% | -176.78% | -47.71% | -11.89% | 15.57% |
| EBIT | -300.87% | -183.61% | -49.46% | -12.62% | 15.53% |
| EBITDA | -289.88% | -177.61% | -49.02% | -12.41% | 15.54% |
| EPS Basic | -208.33% | -105.88% | -11.11% | 18.18% | 39.24% |
| Normalized Basic EPS | -200.00% | -106.25% | -11.76% | 19.05% | 36.73% |
| EPS Diluted | -208.33% | -105.88% | -11.11% | 18.18% | 39.24% |
| Normalized Diluted EPS | -200.00% | -106.25% | -11.76% | 19.05% | 36.73% |
| Average Basic Shares Outstanding | 24.08% | 26.85% | 30.12% | 33.08% | 36.50% |
| Average Diluted Shares Outstanding | 24.08% | 26.85% | 30.12% | 33.08% | 36.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
